Boey (trenibotulinumtoxinE) won EU approval in July 2026. See how serotype E's 8-hour onset and 2-3 week duration compare with serotype A toxins.
Boey (trenibotulinumtoxinE), a serotype E neuromodulator, won European Commission approval on July 17, 2026 for frown lines. Unlike conventional serotype A toxins that work in days and last three to four months, serotype E begins working in about eight hours and fades within two to three weeks. It is not FDA-approved in the US.
Almost every wrinkle-relaxing injection performed today uses a botulinum toxin from serotype A: Botox, Dysport, Xeomin, Jeuveau, and Daxxify are all type A products, all FDA-approved in the US. On July 17, 2026, Allergan Aesthetics (an AbbVie company) received European Commission approval for Boey (trenibotulinumtoxinE), the first and only botulinum toxin serotype E cleared for frown lines. It introduces a fundamentally different timing profile: fast on, fast off.
Boey is approved only in Europe (across all 30 European Economic Area countries) and in Canada, where Health Canada cleared it in June 2026. It is not FDA-approved in the United States. This article explains what a serotype E toxin is and how its onset and duration compare to the serotype A products patients already know.
The European Commission approved Boey (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines (the vertical frown lines between the eyebrows) in adults, when those lines have an important psychological impact. Approval was based on two Phase 3 randomized, double-blind, placebo-controlled trials, M21-500 and M21-508, in which 725 patients received Boey or placebo. Peak effect was seen around Day 7, with lines returning toward baseline in roughly two to three weeks. Reported adverse reactions were uncommon and included eyelid ptosis (0.17 percent) and brow ptosis (0.13 percent).
Allergan Aesthetics describes Boey as targeting SNAP-25, the same nerve-signaling protein serotype A toxins act on, but with rapid uptake into nerve cells and a short-lived type E light chain. That biology is what produces the fast-on, fast-off effect.
Onset: Serotype A toxins typically begin working in about 24 to 72 hours, with maximum effect at roughly 7 to 14 days. Boey (serotype E) may show visible results as early as eight hours after injection.
Duration: Serotype A results generally last about three to four months. Boey wears off in approximately two to three weeks.
Regulatory status: Serotype A products including Botox, Dysport, Xeomin, Jeuveau, and Daxxify are FDA-approved in the US. Boey (serotype E) is not FDA-approved; it is approved in the EU and Canada only. Mechanistically both serotypes cleave SNAP-25 to relax targeted muscles; the difference is speed and staying power, not the basic target.
A toxin that appears within hours and clears within weeks is a different tool than a months-long treatment. A short-duration option could appeal to someone new to neurotoxins who wants to preview the look before committing, or to a patient timing results around a specific event. It is not a longer-lasting or superior product; it is a different profile, and the trade-off is that touch-ups would come far sooner.
For US patients, the practical takeaway is that Boey is not available here and cannot be legally administered in the United States at this time. Whether serotype E is submitted for FDA review, and how it would be priced and positioned against established type A toxins, remains to be seen. Anyone weighing neurotoxin options should discuss onset, duration, and regulatory status with a licensed, qualified provider rather than a product label.